Drug Trial Radar · NCT06903377
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
May 23, 2025
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.
Conditions
- Non-small Cell Lung Cancer
Interventions
ZG005 for InjectionBiological
intravenous infusion
Gecacitinib Hydrochloride TabletsDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event (AE)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.